Catalog #SIM0042

InVivoSIM anti-human IL-13 (Tralokinumab Biosimilar)

Clone Tralokinumab
Reactivities Human, Monkey
Isotype Human IgG4, λ

$235.00 - $8,140.00

$235.00 - $8.00

Choose an Option...
  • 100 mg - $8,140.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Tralokinumab, making it ideal for research use. Tralokinumab is a fully humanized IgG4 monoclonal antibody that reacts with interleukin-13 (IL-13). IL-13 is an inflammatory cytokine that is involved in allergic inflammation and the immune response to parasite infection and is regarded as the primary driver of atopic dermatitis. IL-13 interacts with its high-affinity decoy receptors IL13R1 and IL13R2, and the interaction follows the extracellular IL-13’s internalization and depletion. IL-13 binding to heterodimeric IL-4Rα and IL-13Rα1 activates downstream JAK/STAT pathways. IL-13 stimulates B-cell proliferation and the activation of eosinophils, basophils, and mast cells. IL-13 regulates IL-33 through modulation of the production of interleukin-1 receptor-like 1 (IL1RL1), and IL-13 also regulates the synthesis of interferon-gamma (IFNγ) by synergizing with IL-2. IL-13 antagonizes the Th1-driven proinflammatory immune response and downregulates the synthesis of many proinflammatory cytokines, including IL1, IL6, IL10, IL12, and TNF-alpha. Tralokinumab neutralizes the activity of IL-13 by blocking its interaction with both the IL-13Rα1/IL-4Rα receptor complex and IL-13Rα2 receptors. Tralokinumab binds to IL-13 through an epitope that overlaps the IL-13Rα1 and ILRα2 receptors’ binding sites, thereby preventing binding of IL-13. However, the IL-13 binding affinity to the IL-13Rα2 receptor is greater than that of Tralokinumab. Consequently, freed IL-13 remains able to connect to the IL-13Rα2 receptor. Experiments involving Tralokinumab have reported this antibody to functionally neutralize IL-13, i.e., IL-13Rα1:IL-4Rα interactions in vitro in a range of cell-based assays. In related in vivo experiments involving humanized mouse and cynomolgus monkey antigen challenge models, Tralokinumab was shown to inhibit airway hyperresponsiveness and bronchoalveolar lavage eosinophilia.

Specifications

Isotype Human IgG4, λ
Recommended Isotype Control(s) RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Mutations S228P
Immunogen Human IL-13
Reported Applications in vivo functional assays
in vitro functional assays
ELISA
Flow cytometry
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL gel clotting assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Product FAQs